DEVELOPMENT OF TRANSDERMAL NANOEMULSION FORMULATION FOR SIMULTANEOUS DELIVERY OF PROTEIN VACCINE AND ARTIN-M ADJUVANT

Tri Suciati

2014 · 16 citations · 8 references

Concepts

Abstract

Objective: Vaccine used to enhance immune response is commonly administered via parenteral route. However, it shows some disadvantages. This research aimed to develop a non-invasive vehicle for administering an immunogenic protein and a lectin adjuvant via transdermal route. The hydrophilic nature of protein and lectin became the major challenge faced in this study. Methods: Bovine serum albumin (BSA) was used as protein model and artin-M isolated from cempedak (Artocarpus integrifolia) seed as adjuvant model. Nanoemulsion was formulated as oil in water type and prepared by self-nanoemulsification method. The formulation consisted of virgin coconut oil (VCO), Tween 80, and PEG 400 as oil phase, surfactant, and co-surfactant, respectively. BSA and artin-M were incorporated into the oil phase as co-lyophilized solid dispersion in PEG 20000. The nanoemulsion was characterized by BSA entrapment efficiency, hemagglutination activity of artin-M, and stability testing using freeze thaw conducted by alternating the storage at room temperature and 4 °C up to 6 cycles. Results: The addition of PEG 20000 in solid dispersion at the rasio of 1:1 to BSA markedly increased BSA entrapment efficiency in oil phase to 98.6 ± 0.15%. Artin-M incorporated using the same method was also maintained its activity as shown by hemagglutination testing. The freeze thaw testing revealed the stability of nanoemulsion stored in the fridge with no-aggregation observed. The globule diameter was maintained at the size of 42.7 ± 0.9 nm with polydispersity index of 0.321 ± 0.01. Conclusion: The nanoemulsion is potensial as simultaneous transdermal delivery of protein vaccine and lectin adjuvant.

References

8